Cybin has announced that it has submitted an Investigational New Drug application to the U.S. FDA for its Phase I/IIa first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analogue, for the treatment of major depressive disorder.
Optimi Health has been engaged by Filament Health to supply psilocybin mushrooms cultivated in Optimi’s recently inaugurated 20,000 square foot EU-GMP Princeton, British Columbia facility in the form of whole, dried mushroom fruiting bodies for potential drug development, testing, and analysis by Filament’s research team.
In this piece for The Guardian, Josiah Hesse gives us an insight into exactly what went on at “The Psychedelic House of Davos.”
Albert Labs has announced Sara Tai, Senior Lecturer in Clinical Psychology from Manchester University, as Principal Investigator for its upcoming trial. The trial will evaluate the safety and efficacy of KRN-101, a psilocybin-based medicine, for the treatment of cancer-related distress.
Based on a positive pre-IND meeting with the U.S. FDA, Ceruvia Lifesciences has submitted an Investigation New Drug (IND) application to begin a Phase II clinical trial for the treatment of obsessive-compulsive disorder with psilocybin Preliminary results from the Ceruvia funded pilot Phase II study taking place at Yale School of Medicine demonstrate rapid and robust improvement …
Clerkenwell Health has announced the addition of Dr David Erritzoe, Dr Dea Siggaard Stenbæk, Dr Kim Kuypers and Dr James Stone to its advisory board from Danish, Dutch and British universities.
The Oregon Health Authority (OHA) has adopted the first subset of rules related to psilocybin products, testing and training programs. These rules are needed to implement ORS chapter 475A, the Oregon Psilocybin Services Act. The rules specify curriculum requirements for programs planning to train people interested in facilitating psilocybin services in Oregon, as well as initial …
This great article from Jason Silva for Forbes details what exactly is happening at the World Economic Forums’ annual meeting in Davos in relation to psychedelic medicine.
Researchers at the University of California, Davis, and the University of Colorado Anschutz Medical Campus plan to screen hundreds of compounds to discover new, non-hallucinogenic treatments for substance use disorders. The research is funded by a $2.7 million grant from the US National Institute on Drug Abuse.
COMPASS Pathways has presented positive data from the largest randomised, controlled, double-blind study of psilocybin therapy ever completed, at the American Psychiatric Association annual meeting in New Orleans. The study showed that a single 25mg dose of COMP360 psilocybin, in combination with psychological support, was associated with a highly statistically significant reduction in depressive symptoms after …